255 related articles for article (PubMed ID: 27366947)
1. The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug.
Song P; Yao X; Zhong T; Zhang S; Guo Y; Ren W; Huang D; Duan XC; Yin YF; Zhang SS; Zhang X
Oncotarget; 2016 Jul; 7(30):48467-48480. PubMed ID: 27366947
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo.
Duan XC; Yao X; Zhang S; Xu MQ; Hao YL; Li ZT; Zheng XC; Liu M; Li ZY; Li H; Wang JR; Feng ZH; Zhang X
Int J Nanomedicine; 2019; 14():195-204. PubMed ID: 30636872
[TBL] [Abstract][Full Text] [Related]
3. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X
Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370
[TBL] [Abstract][Full Text] [Related]
4. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
5. A Paclitaxel Prodrug Activatable by Irradiation in a Hypoxic Microenvironment.
Zhou S; Hu X; Xia R; Liu S; Pei Q; Chen G; Xie Z; Jing X
Angew Chem Int Ed Engl; 2020 Dec; 59(51):23198-23205. PubMed ID: 32852145
[TBL] [Abstract][Full Text] [Related]
6. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.
Duan XC; Peng LY; Yao X; Xu MQ; Li H; Zhang SQ; Li ZY; Wang JR; Feng ZH; Wang GX; Liao A; Chen Y; Zhang X
Drug Deliv; 2021 Dec; 28(1):800-813. PubMed ID: 33866918
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles Containing High Loads of Paclitaxel-Silicate Prodrugs: Formulation, Drug Release, and Anticancer Efficacy.
Han J; Michel AR; Lee HS; Kalscheuer S; Wohl A; Hoye TR; McCormick AV; Panyam J; Macosko CW
Mol Pharm; 2015 Dec; 12(12):4329-35. PubMed ID: 26505116
[TBL] [Abstract][Full Text] [Related]
8. Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.
Shan L; Liu M; Wu C; Zhao L; Li S; Xu L; Cao W; Gao G; Gu Y
Int J Nanomedicine; 2015; 10():5571-91. PubMed ID: 26366078
[TBL] [Abstract][Full Text] [Related]
9. Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells.
Satsangi A; Roy SS; Satsangi RK; Vadlamudi RK; Ong JL
Mol Pharm; 2014 Jun; 11(6):1906-18. PubMed ID: 24847940
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, Biological Evaluation and Low-Toxic Formulation Development of Glycosylated Paclitaxel Prodrugs.
Mao Y; Zhang Y; Luo Z; Zhan R; Xu H; Chen W; Huang H
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563132
[TBL] [Abstract][Full Text] [Related]
11. Self-Assembled Tumor-Penetrating Peptide-Modified Poly(l-γ-glutamylglutamine)-Paclitaxel Nanoparticles Based on Hydrophobic Interaction for the Treatment of Glioblastoma.
Yu J; Sun L; Zhou J; Gao L; Nan L; Zhao S; Peng T; Han L; Wang J; Lu W; Zhang L; Wang Y; Yan Z; Yu L
Bioconjug Chem; 2017 Nov; 28(11):2823-2831. PubMed ID: 28968068
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat.
Ke XY; Zhao BJ; Zhao X; Wang Y; Huang Y; Chen XM; Zhao BX; Zhao SS; Zhang X; Zhang Q
Biomaterials; 2010 Aug; 31(22):5855-64. PubMed ID: 20430438
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
14. Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells.
Lv Y; Xu C; Zhao X; Lin C; Yang X; Xin X; Zhang L; Qin C; Han X; Yang L; He W; Yin L
ACS Nano; 2018 Feb; 12(2):1519-1536. PubMed ID: 29350904
[TBL] [Abstract][Full Text] [Related]
15. A new prodrug of paclitaxel: synthesis of Protaxel.
Seligson AL; Terry RC; Bressi JC; Douglass JG; Sovak M
Anticancer Drugs; 2001 Apr; 12(4):305-13. PubMed ID: 11335786
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier.
Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Chen D
J Drug Target; 2015 May; 23(4):311-22. PubMed ID: 25539074
[TBL] [Abstract][Full Text] [Related]
17. Lipoamino acid prodrugs of paclitaxel: synthesis and cytotoxicity evaluation on human anaplastic thyroid carcinoma cells.
Pignatello R; Paolino D; Pantò V; Pistară V; Calvagno MG; Russo D; Puglisi G; Fresta M
Curr Cancer Drug Targets; 2009 Mar; 9(2):202-13. PubMed ID: 19275760
[TBL] [Abstract][Full Text] [Related]
18. pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice.
Dalela M; Shrivastav TG; Kharbanda S; Singh H
ACS Appl Mater Interfaces; 2015 Dec; 7(48):26530-48. PubMed ID: 26528585
[TBL] [Abstract][Full Text] [Related]
19. PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation.
Jiang X; Xin H; Sha X; Gu J; Jiang Y; Law K; Chen Y; Chen L; Wang X; Fang X
Int J Pharm; 2011 Nov; 420(2):385-94. PubMed ID: 21920419
[TBL] [Abstract][Full Text] [Related]
20. D-α-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells.
Bao Y; Guo Y; Zhuang X; Li D; Cheng B; Tan S; Zhang Z
Mol Pharm; 2014 Sep; 11(9):3196-209. PubMed ID: 25102234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
